Clinical trials: In-patients Assessment of Vital Signs
Malignant Glioma
Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma
The objective of this study is to determine the survival status of patients enrolled in study GLI01S (all-case observational study).
- Trial name
- NCT02300506
- Testing
- No intervention
- Where
- 2 sites in Japan
- Volunteers
- 507 people
- Sponsor
- Eisai Co., Ltd.
Vital Sign Evaluation
A Multi-Center Prospective Open Label Study of a Web-based Application for Pulse Rate in Adult Patients
Evaluating the Accuracy of a Web-Based Application - Vital Sign Measurement Platform Description This single-arm cohort, open-label, and multi-center study is designed to evaluate the accuracy of a web-based application designed…
- Trial name
- NCT05853380
- Testing
- Informed Vital Core App
- Where
- 6 sites in United States
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Mindset Medical
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic
An Open-label Extension Trial of HZNP-HZN-825-301 in Adult Participants With Diffuse Cutaneous Systemic Sclerosis (Diffuse Cutaneous SSc)
Primary Objectives: 1. The primary efficacy objective is to assess the efficacy of 52 weeks of open-label treatment with HZN-825 in participants with diffuse cutaneous systemic sclerosis, as measured by change from both baselines…
- Trial name
- NCT05626751
- Testing
- HZN-825
- Where
- 65 sites in United States, Argentina and 13 more
- Volunteers
- 174 people
- Sponsor
- Amgen
Vital Sign Monitoring
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03356184
- Testing
- The Rhea Vital Sign Vigilance Device Group, The Earlysense System Device Group
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Darma Inc.
Vital Sign Monitoring
Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients
This study compares both of the investigational device and reference device to the gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03332147
- Testing
- Investigational Group, reference group-Earlysense system
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Darma Inc.
Vital Sign Monitoring
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients
This study comparing both of the investigational device and reference device to gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03257956
- Testing
- Investigational Group, reference group
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Darma Inc.
No Specific Medical Conditions or Disease States
Pilot Clinical Evaluation of Dozee VS, a Contactless Continuous Vital Parameters Monitoring System in Hospital Patients
The Dozee VS device developed by Turtle Shell Technologies Pvt. Ltd., is a contactless continuous vital parameters monitoring system.
- Trial name
- DZUSFDA21 (NCT05153460)
- Testing
- Telemetry and manual monitoring vs Contactless monitoring devices
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Turtle Shell Technologies Pvt. Ltd.
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients
The main goal of this phase llb study is to compare the efficacy and safety of two doses of HEC585 tablets with placebo which is a look-alike substance that contains no active drug in patients with progressive fibrosing…
- Trial name
- NCT05139719
- Testing
- HEC585 dose A, HEC585 dose B
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
In-patients Assessment of Vital Signs
Data Collection Study for RFP (Respiration From Plethysmogram)
The study will be conducted in hospitalised patients who undergo spot-check monitoring of vital signs as part of their routine care.
- Trial name
- SAT+ (NCT06633861)
- Testing
- spot-check measurement
- Where
- United Kingdom
- Volunteers
- 86 people
- Sponsor
- Philips Clinical & Medical Affairs Global
Vital Sign Monitoring
Pilot Clinical Evaluation of the RHEA Vital Sign Vigilance System in Hospital Patients Patients
This study comparing both of the investigational device and reference device to gold standard Patient Monitor of the accuracy of heart rate and respiratory rate monitoring.
- Trial name
- NCT03269643
- Testing
- Investigational Group, Reference group
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Darma Inc.